2025年9月10日，公司董事长苏恩本先生、公司财务总监倪文先生、公司董 事会秘书刘葱女士、公司独立董事万遂人先生、公司独立董事鞠熀先先生、公司 独立董事凌华女士出席了本次业绩说明会。公司就2025年半年度经营状况、财务 状况、产品等问题与投资者进行互动交流和沟通，在信息披露允许的范围内就投 资者普遍关注的问题进行了回答。 二、本次会议投资者提出的主要问题及公司的回复情况 公司在说明会上就投资者关心的问题给予了回答，主要问题及答复整理如下： 证券代码：603387 证券简称：基蛋生物 公告编号：2025-040 基蛋生物科技股份有限公司 关于 2025 年半年度业绩网上说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）于2025年9月10日 14:00-15:00在上证所信息网络有限公司上证路演中心平台（以下简称"上证路 演中心"）采用网络互动方式召开"基蛋生物2025年半年度业绩说明会"。关于 本次业绩说明会的召开事项，公司已于2025年8月30日在《上海证券报 ...

Group 1 - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.09 yuan per share (tax included) for A-shares [2] - The record date for the dividend is set for September 12, 2025, and the ex-dividend date is September 15, 2025 [2]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-039 基蛋生物科技股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.09元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/12 | － | 2025/9/15 | 2025/9/15 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本507,153,517股为基数，每股派发现 金红利0.09元（含税），共计派发现金红利45,643,816.53元。 | 股份类别 | 股权登记日 | 最后交易 ...

Core Points - Getein Biotech, Inc. is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals aimed at improving corporate governance and operational efficiency [1][3][4] Group 1: Meeting Proposals - Proposal 1 involves the cancellation of the supervisory board and the amendment of the company's articles of association to enhance governance structure [3][4] - Proposal 2 includes multiple amendments to governance-related systems, such as the rules for board meetings, shareholder meetings, and the independent director work system [1][3][4] - The meeting will also address the abolition of the supervisory board's procedural rules and the revision of the external guarantee management system [1][3][4] Group 2: Meeting Procedures - The meeting is scheduled for September 15, 2025, at 14:00, and will be held both in-person and via an online voting system [2][3] - Shareholders must register and provide identification to participate, and they will have the right to speak and vote on the proposals presented [2][3] - Voting will be conducted through a named voting method, and all proposals will require a clear choice of "agree," "disagree," or "abstain" [2][3][4] Group 3: Governance Changes - The proposed changes aim to align the company's governance with the requirements of the Company Law and Securities Law of the People's Republic of China [3][4] - The amendments are designed to protect the rights of shareholders and ensure the company's operations are conducted in a transparent and efficient manner [3][4] - The company emphasizes the importance of maintaining order during the meeting and protecting the rights of all shareholders present [2][3]

基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议资料 基蛋生物科技股份有限公司 Getein Biotech,Inc. 2025 年第一次临时股东大会 会议资料 中国 南京 二〇二五年 九月 1 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议资料 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议资料目录 | 序号 | | 会议资料名称 | | --- | --- | --- | | 1 | | 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议须知 | | 2 | | 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议议程 | | 3 | | 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议议案 | | 议案 | 1 | 关于取消监事会并修订《公司章程》的议案 | | 议案 | 2.00 | 关于修订及制定公司治理相关制度的议案 | | 议案 | 2.01 | 关于修订《董事会议事规则》的议案 | | 议案 | 2.02 | 关于修订《股东会议事规则》的议案 | | 议案 | 2.03 | 关于废止《监事会议事规则》的议案 | | 议案 | ...

据证券之星公开数据整理，近期基蛋生物（603387）发布2025年中报。截至本报告期末，公司营业总收 入5.13亿元，同比下降17.0%，归母净利润1.09亿元，同比下降25.88%。按单季度数据看，第二季度营 业总收入2.69亿元，同比下降9.3%，第二季度归母净利润4450.13万元，同比下降26.8%。本报告期基蛋 生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达177.8%。 交易性金融资产变动幅度为15.79%,原因:投资银行理财产品增加。 应收款项融资变动幅度为-42.15%,原因:银行承兑汇票减少。 预付款项变动幅度为15.47%,原因:预付供应商货款增加。 一年内到期的非流动资产变动幅度为124.43%,原因:银行长期大额存单一年内到期的金额增加。 其他流动资产变动幅度为39.29%,原因:预缴企业所得税增加。 本次财报公布的各项数据指标表现一般。其中，毛利率69.36%，同比增0.14%，净利率20.05%，同比减 17.95%，销售费用、管理费用、财务费用总计1.46亿元，三费占营收比28.39%，同比减0.92%，每股净 资产5.29元，同比增4.1%，每股经营性现金流0. ...

Group 1 - The company reported a revenue of 513 million yuan for the first half of 2025, representing a year-on-year decline of 17.00% [1] - The net profit attributable to the parent company was 109 million yuan, down 25.88% year-on-year [1] - The net profit excluding non-recurring items was 93.23 million yuan, reflecting a year-on-year decrease of 28.52% [1]

Group 1 - The company,基蛋生物, announced the resignation of its securities representative,谢玉鑫, due to job changes, and appointed王娇 as the new representative [1] - The company will hold its fourth board meeting on August 29, 2025, to review the appointment of the new securities representative [1] - For the year 2024, the company's revenue composition is 100% from in vitro diagnostics [1] Group 2 - As of the report, the market capitalization of基蛋生物 is 4.3 billion yuan [1]

Core Viewpoint - Getein Biotech, Inc. reported a decline in revenue and net profit for the first half of 2025, with a focus on maintaining a strong position in the in vitro diagnostics (IVD) market despite challenges [1][2]. Financial Performance - Revenue for the first half of 2025 was approximately RMB 512.69 million, a decrease of 17% compared to RMB 617.67 million in the same period last year [2]. - Total profit for the period was RMB 110.53 million, down 33.49% from RMB 166.18 million year-on-year [2]. - Net profit attributable to shareholders was RMB 108.81 million, reflecting a 25.88% decline from RMB 146.81 million in the previous year [2]. - The company proposed a cash dividend of RMB 0.9 per 10 shares, amounting to a total distribution of approximately RMB 45.64 million, which represents 41.95% of the net profit for the period [1]. Industry Overview - The global IVD market is projected to reach USD 109.2 billion in 2024 and is expected to grow significantly, driven by factors such as policy support, aging populations, and rising chronic disease rates [4][5]. - In China, the IVD market has experienced rapid growth due to increased healthcare demand, improved medical insurance coverage, and advancements in domestic technology [5][6]. - The POCT segment is one of the fastest-growing areas in the IVD market, driven by the convenience and speed of testing, with significant potential for future growth [6]. Company Strategy and Product Development - The company has established eight major technology platforms, including POCT, chemiluminescence, biochemical detection, and molecular detection, to meet clinical needs [7][9]. - Getein has transitioned from a single POCT product line to a diverse range of products, including high-throughput and automated solutions for various healthcare settings [9][10]. - The company is actively expanding its market presence both domestically and internationally, with a focus on building a robust sales network through partnerships with over 3,000 distributors [12][13]. Regulatory and Market Position - As of June 30, 2025, the company held a total of 3,245 product registration certificates, with 460 of these being domestic [11][12]. - Getein's products are now available in 67 countries and regions, with a total of 2,785 product import licenses obtained [12][11]. - The company is committed to maintaining high-quality standards in production, adhering to ISO13485 quality management systems, and ensuring compliance with medical device regulations [14][15].

Core Viewpoint - The report highlights the financial performance and operational developments of Getein Biotech, indicating a decrease in revenue and profit while emphasizing ongoing innovation and market expansion efforts [1][2][3]. Financial Performance - Total assets at the end of the reporting period reached approximately CNY 3.91 billion, an increase of 5.47% compared to the previous year [3]. - Operating revenue for the first half of 2025 was approximately CNY 512.69 million, representing a decrease of 17.00% year-on-year [3]. - Total profit amounted to approximately CNY 110.53 million, down 33.49% from the previous year [3]. - Net profit attributable to shareholders was approximately CNY 93.23 million, a decrease of 28.52% year-on-year [3]. - The cash dividend proposed is CNY 0.9 per 10 shares, accounting for 41.95% of the net profit for the first half of 2025 [2]. Business Operations - The company continues to focus on its core business, with the chemical luminescence segment generating revenue of approximately CNY 150 million, a year-on-year increase of 10.64% [7]. - The company has developed 104 chemical luminescence detection projects, achieving full coverage of common clinical diseases [7]. - The Metis600 and Metis7000 automated biochemical immunoassay lines have been upgraded to enhance efficiency and adaptability for clinical needs [8][9]. - The GN7000/GN7120 automatic nucleic acid amplification analyzers have been launched, achieving significant market penetration with nearly 60 units installed since December 2024 [10]. Innovation and R&D - The company holds a total of 383 patents, including 57 invention patents, indicating a strong focus on innovation [11]. - The introduction of self-developed raw materials has increased the self-sufficiency rate of key materials to over 90% [13]. - The company is committed to expanding its product line and enhancing the performance of existing products to reduce production costs [13]. International Expansion - The company has established product entry permits in 67 countries, with nearly 2800 products approved for import [14]. - The international marketing strategy includes both online and offline channels, enhancing brand recognition and market share [14]. - The company has participated in exhibitions in Dubai and Nigeria, further promoting its global presence [14]. Quality Management - The company adheres to strict quality management standards, aligning with international regulations and certifications [15]. - A comprehensive quality management system has been established, covering all stages from R&D to delivery [15]. - The company has conducted multiple training sessions to enhance the skills of its service team, ensuring high customer satisfaction [16].